FDA Brief

Company record

Chengdu Brilliant Biopharmaceutical Co., Ltd.

1 FDA warning letter since 2023 and 0 recalls in the last 12 months.

Get an email the day FDA posts anything new about Chengdu Brilliant Biopharmaceutical Co., Ltd..

Warning letters

  1. Chengdu Brilliant Biopharmaceutical Co., Ltd.

    FDA warns Chengdu Brilliant over CGMP failures in semaglutide API, including no process validation and missing raw-material identity tests.

    High risk